ASCO ASPIRE COP: Alliance for Support and Prevention of irAEs
LightNews LightNews
banner
aspire-cop.bsky.social
ASCO ASPIRE COP: Alliance for Support and Prevention of irAEs
@aspire-cop.bsky.social
55 followers 70 following 32 posts
It takes a village! Join our Community of Practice in uniting the global medical community to enhance care, education, research, and advocacy for immune-related adverse events #irAE for people living with cancer #ASPIRE #ASCO25
Posts Replies Media Videos
aspire-cop.bsky.social
Sign up now! 2026 ASPIRE-IOTOX Symposium at MDAnderson April 24-25, 2026. Join us to discuss #irAE! mdanderson.cloud-cme.com/course/cours... @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social
2026 IOTOX Symposium: Delivering What Matters - Patient-Centered through IOTOX Translational Science - MDA - Continuing Education (CE)
MDA, 2026 IOTOX Symposium: Delivering What Matters - Patient-Centered through IOTOX Translational Science, 4/24/2026 1:30:00 PM - 4/25/2026 4:00:00 PM, <p>This symposium is designed to create a space ...
mdanderson.cloud-cme.com
November 17, 2025 at 4:17 PM
aspire-cop.bsky.social
📢 Join us for ASPIRE Consortium's Global Session 🌍 Collaborating Across Europe: Advancing Care for irAEs
🎙️ Featuring @drjnaidoo.bsky.social + panel
📅 Sept 15, 2025
🕒 Time: 15:00–16:00 (Central US Time)
💻 Zoom Link: partners.zoom.us/j/82978479128
🔢 Meeting ID: 829 7847 9128
@ascocancer.bsky.social
Join our Cloud HD Video Meeting
Zoom is the leader in modern enterprise cloud communications.
partners.zoom.us
September 12, 2025 at 7:27 PM
Reposted by ASCO ASPIRE COP: Alliance for Support and Prevention of irAEs
aspire-cop.bsky.social
Mark your calendars! ASPIRE-IOTOX Symposium April 24-25, 2026 at MD Anderson Cancer Center #irAE #immunotherapy @sitcancer.bsky.social @ascocancer.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social @mdanderson.bsky.social
August 18, 2025 at 2:39 PM
aspire-cop.bsky.social
Mark your calendars! ASPIRE-IOTOX Symposium April 24-25, 2026 at MD Anderson Cancer Center #irAE #immunotherapy @sitcancer.bsky.social @ascocancer.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social @mdanderson.bsky.social
August 18, 2025 at 2:39 PM
aspire-cop.bsky.social
Check out the Aug 2025 #ASPIRE newsletter to hear the latest in #irAEs. Do not miss our quarterly case conference Tues, Aug 19th at 5:30pm CST. @ascocancer.bsky.social @kerryreynoldsmd.bsky.social @funchainmd.bsky.social @kmittalmd.bsky.social mailchi.mp/759095cedbb0...
ASPIRE August Newsletter
mailchi.mp
August 18, 2025 at 2:37 PM
aspire-cop.bsky.social
📘 Just launched: the first-ever clinical casebook focused solely on immune-related toxicities. 65 expert-contributed cases across 10+ organ systems. Essential reading for the #irAE frontlines. Grab your copy 👉 link.springer.com/book/10.1007...
#irAE #OncologyBooks @ascocancer.bsky.social #ASPIRE
Challenging Cases in Immunotherapy Related Organ Toxicities
This is a book that focuses on examples of challenging cases with toxicities presented in different organ systems
link.springer.com
June 27, 2025 at 12:01 AM
aspire-cop.bsky.social
🧠 Stay sharp with the latest in #irAE research! From duplilumab in cutaneous toxicities to survival outcomes with inpatient ICI use—our curated #ASPIRE reading list 🔥.
Start reading now in our latest newsletter: mailchi.mp/325da8534919...
#Immunotherapy #irAE #MedEd @kmittalmd.bsky.social
ASPIRE June Newsletter
mailchi.mp
June 26, 2025 at 11:59 PM
aspire-cop.bsky.social
Missed #ASPIRE June 17 webinar? 🎥 Now available on-demand! Dive into cutting-edge #ASCO updates on #irAE education, biomarkers, & translation. Must watch the evolving #immunotherapy landscape. 🎯 Link in our latest newsletter:
mailchi.mp/325da8534919... @funchainmd.bsky.social
ASPIRE June Newsletter
mailchi.mp
June 26, 2025 at 11:57 PM
Reposted by ASCO ASPIRE COP: Alliance for Support and Prevention of irAEs
funchainmd.bsky.social
Wrapping up #ASCO24 with this thought: let’s get more people under the survival curve and lift it up - it might be prolonged survival, it might even be cure. Every moment counts.

May we all walk into our post ASCO lives inspired ✨ 📈 @ascocancer.bsky.social @aspire-cop.bsky.social
stevenartandi.bsky.social Steven Artandi @stevenartandi.bsky.social · May 28
SCI leader @funchainmd.bsky.social & others review treatment strategies for #MetastaticMelanoma: BRAF/MEK inhibitors improve survival; #TILtherapy shows 30% durable response; novel TCR-T & CD3 bispecifics emerging; ICI viable even with irAEs, age, or transplant history.
ascopubs.org
June 4, 2025 at 7:11 PM
aspire-cop.bsky.social
🚀 That's a wrap #ASCO25! Join ASCO’s #ASPIRE Community of Practice, the go-to hub for clinicians addressing immune-related toxicities!
🌟 FREE access for non-oncologists (for a limited time)
💬 Engage in virtual meetings, expert discussions, and access curated content!
docs.google.com/forms/d/1zfl...
ASPIRE MEMBERSHIP FORM
To unite the global medical community to advance clinical practice, education, and research in the prevention, diagnosis, and management of immune-related adverse events (irAEs) from immunomodulating ...
docs.google.com
June 3, 2025 at 1:16 PM
Reposted by ASCO ASPIRE COP: Alliance for Support and Prevention of irAEs
funchainmd.bsky.social
Alright y’all - last day of #irAE content at #ASCO25 @aspire-cop.bsky.social @ascocancer.bsky.social

Monday 6/2

11:30a Bi/Multi-specific Antibodies S406
➡️Giuseppe Curigliano
➡️Enriquita Felip
➡️Funda Meric Bernstam

3p Beyond Checkpoint E450b
➡️me 😇
➡️Evan Lipson
➡️Jason Luke
funchainmd.bsky.social Pauline Funchain @funchainmd.bsky.social · May 30
🗓️ UPDATED! #irAE guide to #ASCO25

Fri 5/30
1p Academic/Commun Tox Care E350
4p ASPirE CoP - join us! E253cd

Sun 6/1
8a Rare/Severe Cases S406
9:30a BiTES Arie
2:30p Tox incl CART E451

Mon 6/2
11:30a Bi/Multi-specific Antibodies S406
1p Beyond Checkpoint E450b

Deets in 🧵👇
funchainmd.bsky.social Pauline Funchain @funchainmd.bsky.social · May 28
🗓️ Hey irAE fam here’s your #irAE guide to #ASCO25

Fri 5/30
1p Academic/Community Tox Care E350
4p ASPirE CoP - join us! E253cd

Sat 5/31
9:30a BiTES Arie

Sun 6/1
8a Rare and Severe Cases S406
2:30p Tox incl CART E451

Mon 6/2
9:30a Bi and Multi-specific Antibodies S406
1p Beyond Checkpoint E450b
June 2, 2025 at 12:26 PM
Reposted by ASCO ASPIRE COP: Alliance for Support and Prevention of irAEs
funchainmd.bsky.social
Phase II ipi nivo rela with IL6 inhibitor sarilumab with ORR 68% - highest reported with IO - and grade 3/4 irAEs 12% - lowest reported with combination IO
Jan Mehnert @nyulangone.bsky.social
#ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social
June 2, 2025 at 3:06 PM
Reposted by ASCO ASPIRE COP: Alliance for Support and Prevention of irAEs
funchainmd.bsky.social
Melanoma rapid #3 ➡️ High fiber diet of 30-50g daily is tolerable, pCR 57% in neoadj group, grade 3+ irAE 28.8%

Took 400 patients screened to enroll 45 🤔

Yiufan Qiu @mdanderson.bsky.social
#ASCO25 @ascocancer.bsky.social
@aspire-cop.bsky.social
June 2, 2025 at 3:24 PM
Reposted by ASCO ASPIRE COP: Alliance for Support and Prevention of irAEs
funchainmd.bsky.social
Melanoma rapid orals #5 ➡️ single dose of neoadj ipi 3 + nivo 1 with 59% major pathological response and 9% grade 3+ TRAE. CD8 PET not predictive.
Sarah Lochrin @mskcc.bsky.social
#ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social
June 2, 2025 at 3:43 PM
Reposted by ASCO ASPIRE COP: Alliance for Support and Prevention of irAEs
funchainmd.bsky.social
Neoadj ipi/nivo is clear winner in melanoma, prompting Genevieve Boland and Diwakar Davar to discuss the CONSTANT communication required between med onc/ surg onc (and relevant subspecialists) perioperatively to address ir-AI or colitis #ASCO25 #irAE @ascocancer.bsky.social @aspire-cop.bsky.social
June 2, 2025 at 6:45 PM
Reposted by ASCO ASPIRE COP: Alliance for Support and Prevention of irAEs
darcyburbage.bsky.social
Honoring all those whose lives have been touched by cancer - your story is unique and powerful, I see you!
#NCSD25
June 1, 2025 at 10:41 AM
aspire-cop.bsky.social
Starting soon! More great #irAE content at #ASCO25, including CAR-T and BiTES @kmittalmd.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social #ASPIRE
June 1, 2025 at 9:29 PM
Reposted by ASCO ASPIRE COP: Alliance for Support and Prevention of irAEs
anmwongnz.bsky.social
Such important work @aspire-cop.bsky.social team. Crucial to collect the right info to improve our understanding of immunotherapy toxicities and plan the right supportive care for our patients

#IOtox #supportivecare #immunotherapy
aspire-cop.bsky.social ASCO ASPIRE COP: Alliance for Support and Prevention of irAEs @aspire-cop.bsky.social · May 30
Did you know the ICD10 codes to identify patients experiencing immunotherapy toxicity? @kmittalmd.bsky.social presents these codes as a system-based approach to capture #irAE impact @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @mazietsangmd.bsky.social @ascocancer.bsky.social
May 30, 2025 at 11:52 PM
Reposted by ASCO ASPIRE COP: Alliance for Support and Prevention of irAEs
kmittalmd.bsky.social
Thank you to the @aspire-cop.bsky.social executive committee for giving me the opportunity to present at this exciting education session at @ascocancer.bsky.social #asco25
May 31, 2025 at 4:58 PM
Reposted by ASCO ASPIRE COP: Alliance for Support and Prevention of irAEs
mazietsangmd.bsky.social
@aspire-cop.bsky.social The very first ASPIRE CoP meeting on #irAE! A historic moment!
May 30, 2025 at 9:11 PM
Reposted by ASCO ASPIRE COP: Alliance for Support and Prevention of irAEs
funchainmd.bsky.social
Starting in 5 min! Be a part of history at the first meeting of @aspire-cop.bsky.social #irAE #ASCO25 @ascocancer.bsky.social
May 30, 2025 at 8:56 PM
aspire-cop.bsky.social
@mazietsangmd.bsky.social describing how to "connect the dots" of #irAE multidisciplinary management across academic and community cancer centers #ASPIRE @ascocancer.bsky.social @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @kmittalmd.bsky.social
May 30, 2025 at 6:43 PM
aspire-cop.bsky.social
Did you know the ICD10 codes to identify patients experiencing immunotherapy toxicity? @kmittalmd.bsky.social presents these codes as a system-based approach to capture #irAE impact @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @mazietsangmd.bsky.social @ascocancer.bsky.social
May 30, 2025 at 6:32 PM
aspire-cop.bsky.social
@kmittalmd.bsky.social presents #ASPIRE #ASCO25 community united in "Advancing Clinical Care, Research, and Advocacy in Immunotherapy-Related Adverse Events" #irAE @funchainmd.bsky.social @kerryreynoldsmd.bsky.social @ascocancer.bsky.social @mazietsangmd.bsky.social @advocatecollab.bsky.social
May 30, 2025 at 6:28 PM
aspire-cop.bsky.social
Kathryn Bollin, MD's #ASCO25 community oncology perspective on "Getting Practical About Care Transitions" in patients with #irAE #OncSky. "Access to immunotherapy has far outpaced evidence to inform how to manage the related side effects" @ascocancer.bsky.social #ASPIRE @pateloncology.bsky.social
May 30, 2025 at 6:18 PM